Last week, readers were most interested in a story about FDA approving Cleveland Diagnostics' prostate cancer test.

The test, which will use Iso-PAS technology, will be developed by Nipro of Japan in collaboration with other companies, institutes, and nonprofit organizations.

The medical center will use PathAI's AISight Dx image management system to evaluate algorithms for a variety of applications.

The company is developing a noninvasive urine-based test for sexually transmitted infections including chlamydia and gonorrhea.

Hims & Hers obtains YourBio's microsampling tech, which the firm said will speed its efforts to improve blood collection, including outside traditional clinical settings.

NEW YORK – Cancer detection company Freenome said Friday that it plans to go public on the Nasdaq through a merger with publicly traded special purpose acquisition company Perceptive Capital Solutions ...

The PCR-based point-of-care test runs on the Cobas Liat platform and returns results for three Bordetella species in 15 minutes.

The funding will support a collaboration between ProtonDx and Imperial College London to evaluate a host gene expression test on a next-gen test system.

The analyzer integrates clinical chemistries, immunoassays, and hematology assays into a single plug-and-play instrument.

The company's Check4 electrochemical detection platform can detect nucleic acid targets from blood or saliva samples in less than five minutes.